Intratumoural Heterogeneity Underlies Distinct Therapy Responses and Treatment Resistance in Glioblastoma.

Cancers (Basel) 2019 Feb 6;11(2). Epub 2019 Feb 6.

Cell and Molecular Biology Department, QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia.

Glioblastomas are the most common and lethal neoplasms of the central nervous system. Neighbouring glioma cells maintain extreme degrees of genetic and phenotypic variation that form intratumoural heterogeneity. This genetic diversity allows the most adaptive tumour clones to develop treatment resistance, ultimately leading to disease recurrence. We aimed to model this phenomenon and test the effectiveness of several targeted therapeutic interventions to overcome therapy resistance. Heterogeneous tumour masses were first deconstructed into single tumour cells, which were expanded independently as single-cell clones. Single nucleotide polymorphism arrays, whole-genome and RNA sequencing, and CpG methylation analysis validated the unique molecular profile of each tumour clone, which displayed distinct pathologic features, including cell morphology, growth rate, and resistance to temozolomide and ionizing radiation. We also identified variable sensitivities to AURK, CDK, and EGFR inhibitors which were consistent with the heterogeneous molecular alterations that each clone harboured. These targeted therapies effectively eliminated the temozolomide- and/or irradiation-resistant clones and also parental polyclonal cells. Our findings indicate that polyclonal tumours create a dynamic environment that consists of diverse tumour elements and treatment responses. Designing targeted therapies based on a range of molecular profiles can be a more effective strategy to eradicate treatment resistance, recurrence, and metastasis.

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11020190DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406894PMC
February 2019
26 Reads

Publication Analysis

Top Keywords

treatment resistance
12
intratumoural heterogeneity
8
targeted therapies
8
tumour
5
resistance
5
distinct pathologic
4
pathologic features
4
features including
4
including cell
4
displayed distinct
4
clone displayed
4
molecular profile
4
profile tumour
4
tumour clone
4
cell morphology
4
variable sensitivities
4
rate resistance
4
resistance temozolomide
4
temozolomide ionizing
4
growth rate
4

References

(Supplied by CrossRef)

Similar Publications